| Objective To verify the predictive value of FRAX by using rheumatoid arthritis (RA) in patients with T2DM. Methods 324 T2DM patients hospitalized in a Grade A hospital from January to May 2023 were selected and divided into OP and non-OP groups, their general clinical data and bone density were collected, and RA option in FRAX was replaced with T2DM for scoring. The differences in general clinical data and corrected FRAX scores were compared between the two groups. The predictive ability of FRAX after RA correction can be analyzed by logistic regression model and ROC curve, and its intervention threshold can be determined by sensitivity and specificity. Ninety-three T2DM patients who hospitalized during June to July 2023 were used to verify their clinical application value. Results The proportion of women, OP group, higher age, longer diabetes duration, previous fracture history, glucocorticoid use and adjusted MOFP and adjusted HFP were higher than the non-OP group; weight and BMI were lower than the non-OP group(P<0.05). In the validation group, the proportion of women, age, duration of diabetes, BMI, adjusted MOFP, and number of adjusted HFP were higher than those without fracture, with P<0.05. Conclusion The correction for FRAX-MOFP 6% or correction for FRAX-HFP 3% had good accuracy as the intervention threshold, and RA correction for FRAX could improve the probability of fracture risk assessment for T2DM patients in western Guangxi. |